ADC Therapeutics SA (ADCT) research

ADC Therapeutics SA
ShareXLinkedInReddit
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Last price
$1.12
As of

ADC Therapeutics SA (ADCT): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-13.

As of . Source: SEC EDGAR filings for ADCT. Method and limitations.

SHARE THIS CARD

Share the ADCT intelligence card

A branded snapshot of ADCT: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion ADCT intelligence card preview
Post to X
LIVE TERMINAL

See ADCT live in the terminal

Track ADCT's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live ADCT terminal, free

Active signals for ADCT

FREE, NO ACCOUNT

Every signal on ADCT, as it fires

You are seeing 5 of 21 signals recorded on ADCT since 2026-07-24.

The five above all landed on 2026-09-06. The other 16 were recorded on 2 other days. 20 of the 21 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in ADCT (2026Q2)

Manager / securityMarket value% portfolioQoQ
Point72 Asset Management, L.P.CUSIP H0036K147 · 2026Q2$3.9M0.00%,
MILLENNIUM MANAGEMENT LLCCUSIP H0036K147 · 2026Q2$3.1M0.00%,
CITADEL ADVISORS LLCCUSIP H0036K147 · 2026Q2$2.2M0.00%,
TWO SIGMA INVESTMENTS, LPCUSIP H0036K147 · 2026Q2$828K0.00%,
D. E. Shaw & Co., Inc.CUSIP H0036K147 · 2026Q2$770K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, ADCT

ADCT against its peers

ADCT's operating margin of -149.3% ranks in the 9th percentile of 16 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-03-31.

MetricADCTPeer medianPercentilen
Revenue FY81.4M USD55.6M USD5616
Gross marginn/a41.0%n/a12
Operating margin-149.3%-9.8%916
Net margin-175.3%-31.2%817
Return on equityn/a-31.9%n/a14

Peers (18): GRUSF, AAWH, BGM, CPIX, DERM, CWBHF, TSNDF, JUSHF, CRDL, AKBA, ELTP, ZYBT, CRLBF, TLPH, LEEEF, SCYX, CGC, PLNH. Left out: ASRT (no annual filing), OGI (period gap), LFCR (no annual filing), CTOR (no annual filing), PHBI (period gap), INCR (period gap), BORAY (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (ADCT: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more ADCT signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ADCTand get the insider, 13F, options, and confluence read in one view.

Open the live ADCT terminal, free